SRPT logo

SRPT
Sarepta Therapeutics Inc

26,728
Mkt Cap
$1.69B
Volume
2.49M
52W High
$107.23
52W Low
$10.42
PE Ratio
-1.91
SRPT Fundamentals
Price
$16.23
Prev Close
$16.09
Open
$16.06
50D MA
$20.16
Beta
1.20
Avg. Volume
2.38M
EPS (Annual)
-$7.13
P/B
1.48
Rev/Employee
$2.63M
$2,254.48
Loading...
Loading...
News
all
press releases
Wedbush Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $29.00
Wedbush cut their target price on Sarepta Therapeutics from $34.00 to $29.00 and set an "outperform" rating on the stock in a report on Monday...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright
HC Wainwright reaffirmed a "sell" rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a research note on Monday...
MarketBeat·4d ago
News Placeholder
Sarepta Therapeutics, Inc. $SRPT Shares Purchased by Vanguard Group Inc.
Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 18.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·4d ago
News Placeholder
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty-eight ratings firms that are presently covering the firm...
MarketBeat·4d ago
News Placeholder
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·6d ago
News Placeholder
Wells Fargo & Company Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $38.00
Wells Fargo & Company decreased their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday...
MarketBeat·7d ago
News Placeholder
Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
read more...
Benzinga·7d ago
News Placeholder
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the...
Business Wire·7d ago
News Placeholder
Erste Asset Management GmbH Has $50.59 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT
Erste Asset Management GmbH boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 65.7% in the 3rd quarter, according to its most recent filing with the...
MarketBeat·7d ago
News Placeholder
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings...
MarketBeat·8d ago
<
1
2
...
>

Latest SRPT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.